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Metastases1. Introduction
More than 70% of cases of ovarian cancer are diagnosed as stage III
and IV at presentation given the vague symptoms and lack of a good
screening technique (American Cancer Society). Even at an advanced
stage, a majority of metastatic disease is conﬁned within the abdominal
cavity. Ovarian cancer metastasizing to the breast is rare; a study of
more than 4000 breast cancer patients found that only 0.07% had dis-
ease originating from the ovary (Hadju and Urban, 1972). While there
have been approximately forty cases of ovarian cancer metastatic to
the breast since its ﬁrst reporting in 1907, caseswheremetastatic breast
diseasewas diagnosed ﬁrst are rarer still (Klein et al., 2010).We report a
patient diagnosed and treated for breast cancer subsequently deter-
mined to be an ovarian primary.
2. Case report
This was a 61 year old patient with a past medical history signiﬁcant
only for hypertension who was found to have a left breast mass
concerning for malignancy on screening mammogram in May 2012.
Shewas referred to surgical oncology after an ultrasound-guided biopsy
was diagnosed as invasive ductal carcinoma. In August 2012, she
underwent amodiﬁed left mastectomy and axillary node dissection. Pa-
thology demonstrated a high-grade papillary carcinoma and stained⁎ Corresponding author at: Emory University, Department of Gynecology and
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15 and mammoglobin (Images 1 and 2). Of note, the tumor was estro-
gen receptor positive and progesterone and her-2/neu receptor nega-
tive. Given concern for a possible metastatic ovarian or peritoneal
serous carcinoma, she had a PET-CT which did not demonstrate any
FDG-avid foci within the abdomen or pelvis and adnexa were noted to
bewithin normal limits. CA-125was 8.2. Shewas referred to gynecolog-
ic oncology for discussion of possible diagnostic laparoscopy versus hys-
terectomy and bilateral salpingo-oophrectomy however, the patient
declined intervention at that time. She underwent adjuvant chemother-
apy (four cycles of doxorubicin and cyclophosphamide followed by two
cycles of paclitaxel) and chest wall radiation with completion in July
2013 and was then placed on anastrozole after.
She followed at regular intervals with her medical oncologist. Notes
indicate that from July 2013 until April of 2015 she was in her usual
state of health and her physical exam was within normal limits. On
April 10, 2015, she presented for follow-up with oncology and
complained of copious discharge from her naval as well as abdominal
fullness. A CT abdomen/pelvis scan demonstrated ascites, omental cak-
ing, concern for a Saint Mary Joseph nodule in the umbilicus, and soft
tissue mass of the right adnexa measuring 1.6 × 3.4 cm. CA-125 was
384.0. She underwent a FNA of the umbilical nodule and paracentesis
with cytology showing papillary serous adenocarcinoma of Muellerian
origin. Of note, the specimen was GATA 3 negative (Image 3). She was
referred to a gynecologic oncologist and ultimately had a debulking pro-
cedurewith residual disease less than tenmillimeters at the completion
of surgery. Final pathology was compared with the slides from the
breast excision and demonstrated similar cytomorphologic features
(Image 4).
3. Literature review and discussion
To our knowledge, there are forty reported cases of ovarian cancer
metastasizing to the breast (Klein et al., 2010). It has been noted that
in these cases, breast metastases present on average two years after ini-
tial diagnosis with ovarian cancer (Ozguroglu et al., 1999). In contrast,
our patient presented with breast cancer more than two and a half
years prior to developing symptoms secondary to ovarian cancer. A
search of the English literature has yielded only one such similar case,
where a patient presented ﬁrst with breast and axillary disease
(Hockstein et al., 1996). While the patient from that case did not have
abdominal symptoms at presentation, work-up found a 6 cm adnexal
mass and elevated CA-125, and thus the patient underwent a stagingthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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toms and diagnosis of the underlying ovarian cancer in our patient, we
hypothesize that the chemotherapeutics used to treat her breast cancer
(known to be efﬁcacious against Muellerian tumors) may have actually
treated her primary disease site.
From the previously described cases, it is known that the most com-
mon histologic variant of ovarian cancer associated withmetastatic dis-
ease to the breast is papillary serous adenocarcinoma (Moore et al.,
1998). As almost 30% of breast cancers metastasize to the ovaries, im-
munohistochemicalmarkers such asGATA 3, GCDFP-15,mammoglobin,
and PAX8 can be used to differentiate primary ovarian versusmetastatic
breast disease; GATA 3 is currently themost sensitivemarker for prima-
ry breast cancer (Sangoi et al., 2015). PAX8 stains tumors of gynecologic
origin only and should be negative for disease with origin in the breast
(Hockstein et al., 1996).
The primary mode of dissemination in ovarian cancer is through di-
rect exfoliation of malignant cells within the peritoneal cavity. The sec-
ond most common mode of metastatic spread is through lymphatic
channels. Hematogenous spread is the least common mode and only
present in 2–3% of patients; the disease sites associated with this
route are most commonly the lung, pericardium, CNS, and bones
(Berek and Hacker, 2015). Certainly, it is this hematogenous spread of
ovarian cancer, which would appear to explain distant breast disease.
Metastatic ovarian cancer with distant disease sites at the breast is
rarewith few cases reported in the literature. This patientwasﬁrst diag-
nosed with a breast cancer two and a half years before symptoms or ra-
diologic ﬁndings of ovarian cancer were noted, making this an
extremely rare presentation. We believe adjuvant chemotherapy used
to treat her breast disease may have treated underlying ovarian cancer
and delayed the presentation.Conﬂict of interest statement
The authors declare that there are no conﬂicts of interest.
Acknowledgments
Thank you to Shannon O'Brien, MD, Department of Pathology and
Laboratory Medicine, Emory University School of Medicine, for the pa-
thology images.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.gore.2015.12.005.
References
American Cancer Society (http://www.cancer.org/cancer/ovariancancer/)
Berek, J.S., Hacker, N.F., 2015. Epithelial ovarian, fallopian tube, and peritoneal cancer. Gy-
necologic Oncology, ﬁfth ed. Wolters Kluwer, Philadelphia.
Hadju, S.I., Urban, J.A., 1972. Cancers metastatic to the breast. Cancer 29, 1691–1696.
Hockstein, S., Keh, P., Lurain, J.R., Fishman, D.A., 1996. Ovarian carcinoma initially present-
ing as metastatic axillary lymphadenopathy. Gynecol. Oncol. 65, 543–547.
Klein, R.L., et al., 2010. Ovarian cancermetastatic to the breast presenting as inﬂammatory
breast cancer: a case report and literature review. J. Cancer 1, 27–31.
Moore, D., Wilson, D., Hurteau, J., 1998. Gynecologic cancers metastatic to the breast.
J. Am. Coll. Surg. 187, 178–181.
Ozguroglu, M., Ersavasti, G., Ilvan, S., 1999. Bilateral inﬂammatory breast metastases of
epithelial ovarian cancer. Am. J. Clin. Oncol. 22 (4), 408–410.
Sangoi, A.R., Shrestha, B., Yang, G., Mego, O., Beck, A.H., 2015. The novel marker GATA 3 is
signiﬁcantly more sensitive than traditional markers mammaglobin and GCDFP15 for
identifying breast cancer in surgical and cytology specimens of metastatic and
matched primary tumors. Appl. Immunohistochem. Mol. Morphol. (epub ahead of
print).
